Clone generation from either hybridoma, phage display or from B cell generates thousands of potential leads. Screening for a primary selection of optimal leads is usually done with an ELISA based Protein-Protein Interaction (PPI).
The hits or compounds with the strongest affinity to the target of interest are picked and follow-up screening is performed in various functional assays to determine the biologic candidate’s therapeutic potential.
We offer multiple chemistries for high throughput antigen-protein elucidation which accoupled with our integrated automation solutions can save your time and move you quickly toward your lead discovery workflows.
With dedicated workstations designed for a diverse variety of applications, along with the ability to customize liquid handling workstations based on your needs, PerkinElmer's innovative automated liquid handling solutions enable you to minimize errors, reduce hands-on time, and increase throughput and reproducibility.
Your job is to move from target to hit to candidate quickly and efficiently – with as little wasted resources as possible. Our drug discovery screening reagents do just that.
Whether you are doing high throughput screening or focused screening, we offer a wide range of validated reagents and kits in Alpha chemiluminescent, LANCE® TR-FRET, DELFIA® TRF, and other assay technologies to suit you screening assay needs.
Modulation of protein interactions can affect signal transduction, growth factor, gene expression, and other factors, making it a promising new avenue for protein-base treatments. Development of protein-based therapeutics requires a thorough understanding of protein function and interactions.
Our protein-protein interaction assays and instruments allow fast, multimode detection of protein-protein interactions for drug discovery.
The full measurement capabilities of our protein-protein interaction analysis technologies include:
